![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GLENMARK TIES UP WITH PAUL CAPITAL OF USA TO DEVELOP DERMATOLOGY PRODUCTS
GLENMARK TIES UP WITH PAUL CAPITAL OF USA TO DEVELOP DERMATOLOGY PRODUCTS
June 5, 2006
Glenmark Pharmaceuticals Inc (GPI), a wholly owned US subsidiary of Glenmark Pharmaceuticals, has announced a royalty deal with Paul Capital Partners Royalty fund, an international healthcare investment fund to develop generic prodcuts in the dermatology portfolio for the billion dollar US markets.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct